Literature DB >> 8895098

Structural requirements for cathepsin B and cathepsin H inhibition by kininogens.

B Bano1, S P Kunapuli, H N Bradford, R W Colman.   

Abstract

Domain 3 (D3) of human kininogens, the major cysteine proteinase inhibitors in plasma, has been shown to be the tightest binding inhibitory domain for cathepsins B and H. D3 was expressed in three fragments as its exon products as follows: exon 7 (Gly235-Gln292), exon 8 (Gln292-Gly328), and exon 9 (Gln329-Met357). Exon products 7, 8, and 9 alone as well as exon product 7 + 9 each exhibited an 1C50 value 5- to 30-fold higher (5-30 microM) than exon products 7 + 8 and 8 + 9 (0.9-1.3 microM) for cathepsins B and H, respectively. However, in turn, the exon products 7 + 8 and 8 + 9 seemed to be less potent inhibitors than the intact D3 (10, 200 nM) or HK (200, 500 nM) molecule. These results clearly indicate that an intact molecule of HK or its domain 3 as a whole is required for optimal inhibition of cathepsins B and H.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895098     DOI: 10.1007/bf01908533

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  21 in total

1.  Characterization of a cathepsin L-like enzyme secreted from human pancreatic cancer cell line HPC-YP.

Authors:  N Yamaguchi; S M Chung; O Shiroeda; K Koyama; J Imanishi
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

2.  Structural organization of the human kininogen gene and a model for its evolution.

Authors:  N Kitamura; H Kitagawa; D Fukushima; Y Takagaki; T Miyata; S Nakanishi
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

Review 3.  Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.

Authors:  L A Liotta
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

4.  A new function of kininogens as thiol-proteinase inhibitors: inhibition of papain and cathepsins B, H and L by bovine, rat and human plasma kininogens.

Authors:  T Sueyoshi; K Enjyoji; T Shimada; H Kato; S Iwanaga; Y Bando; E Kominami; N Katunuma
Journal:  FEBS Lett       Date:  1985-03-11       Impact factor: 4.124

5.  Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain.

Authors:  H N Bradford; B A Jameson; A A Adam; R P Wassell; R W Colman
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

Review 6.  Cathepsin B, Cathepsin H, and cathepsin L.

Authors:  A J Barrett; H Kirschke
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases.

Authors:  G Salvesen; C Parkes; M Abrahamson; A Grubb; A J Barrett
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

8.  Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 of domain 3 in the heavy chain of high molecular weight kininogen.

Authors:  S P Kunapuli; H N Bradford; B A Jameson; R A DeLa Cadena; L Rick; R P Wassell; R W Colman
Journal:  J Biol Chem       Date:  1996-05-10       Impact factor: 5.157

9.  Elastinolytic activity of human cathepsin L.

Authors:  R W Mason; D A Johnson; A J Barrett; H A Chapman
Journal:  Biochem J       Date:  1986-02-01       Impact factor: 3.857

10.  Cathepsin B: association with plasma membrane in metastatic tumors.

Authors:  B F Sloane; J Rozhin; K Johnson; H Taylor; J D Crissman; K V Honn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

View more
  1 in total

Review 1.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.